Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Stopped early · Phase 2

Conditions studied: Soft Tissue Sarcoma

In brief

The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.

Key facts

Study ID

NCT00717522

Run by

Celgene

People needed

7

Starts

2008-08-01

Expected to finish

2009-01-01

Last updated by the study team

2019-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be > 18 years of age
• Must have histologically confirmed soft tissue sarcoma
• Must have locally recurrent unresectable, or metastatic soft tissue sarcoma, and have failed or relapsed after a minimum of one and a maximum of 3 prior systemic anticancer therapy regimens
• Must have measurable or evaluable disease determined as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• Must have documented disease progression (PD) determined as per RECIST criteria within 3 months prior to study enrollment
• Must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

You may not qualify if…

• Pregnant or lactating females
• Prior therapy with thalidomide or lenalidomide
• Prior use of experimental/investigational drug therapy < 3 months prior to treatment initiation
• Prior chemotherapy, biologic or immunotherapy < 3 weeks prior to treatment initiation
• Prior radiotherapy < 3 weeks prior to treatment initiation
• Prior major surgery < 3 weeks prior to treatment initiation
• Absolute neutrophil count (ANC) < 1.5 x 109 cells/L
• Platelet count < 100 x 109cells/L
• Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/serum glutamic pyruvate transaminase (ALT/SGPT) > 3.0 x upper limit of normal (ULN) or > 5.0 x ULN in the presence of demonstrable liver metastases
• Known active central nervous system (CNS) metastases

Where it is running

• Sarcoma Oncology Center — Santa Monica, California, United States
• Kootenai Cancer Center — Coeur d'Alene, Idaho, United States
• Nebraska Methodist Hospital — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.